[24 May 2013, Hong Kong] Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or the "Company"; stock code: 600196-SH, 02196-HK; and, together with its subsidiaries, the "Group"), a leading healthcare company in the PRC, announced that through Fosun Industrial (HK) Co., Ltd., its wholly-owned subsidiary, transferred a total of 16,050,000 shares of Guizhou Tongjitang Pharmaceutical Co., Ltd. (“Tongjitong Pharmaceutical”) common stock (constitute 32.1% of its total authorized and issued capital stock) to Winteam Pharmaceutical Group Limited ( “Winteam Pharma”) at a transfer price of approximately 847million RMB. Upon completion of the transaction, Fosun Pharma will no longer hold Tongjitong Pharmaceutical shares.

Tongjitong Pharmaceutical is a proprietary Chinese pharmaceutical company engaged in scientific research, production and distribution. Its principal products include Xianling Gubao Capsules and Tablets, Moisturizing and Anti-Itching Capsules, Zaoren Anshen Capsules, Jingshu Granules and Fengshi Gutong Grandules etc. Winteam Pharma, established in 1992, is a large scale modern pharmaceutical enterprise under China National Pharmaceutical Group Corporation’s (“Sinopharm”) holding. The principal business activities of the Group are the manufacture and sale of traditional Chinese medicine and pharmaceutical products in the PRC with focuses on respiratory system drugs, nasal preparations, cerebro-cardiovascular drugs, and rheumatic diseases and bone injuries drugs.

Mr. Chen Qiyu, Chairman of Fosun Pharma, said, “The decision to transfer Tongjitong Pharmaceutical shares is based on the overall strategy of the Company’s comprehensive development. This enables Fosun Pharma to better allocate its resources to its core holding business developments, to conduct extensive medical research, and to upgrade its industrial status through international mergers and acquisitions. ”